Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant.
about
Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantationViraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialPrevention of transfusion-transmitted cytomegalovirus infection.Opportunistic infections after blood and marrow transplantation.Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.Prevention and treatment of viral infections in stem cell transplant recipients.Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status.Prevention of viral infections after bone marrow transplantation.Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction.Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation.Antiviral therapy: current concepts and practicesEfficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipientsOligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116).Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China.Cytomegalovirus pneumonitis and bone marrow transplantation: identification of a specific high risk groupHow we treat cytomegalovirus in hematopoietic cell transplant recipients.Cytomegalovirus infection/disease after hematopoietic stem cell transplantation.Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.Immunotherapy for infectious diseases in haematological immunocompromise.Viral infections in leukemia and bone marrow transplant patients.Detection of neutralizing antibodies against human cytomegalovirus: influence of strain variation.Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.Management of cytomegalovirus infection in haemopoietic stem cell transplantation.Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.
P2860
Q24241083-A13DAA64-16F9-42D3-8F21-4701D6FD019AQ33429827-A00D561F-1203-4506-ADE7-E232C0A40CA0Q33650397-A4693B59-4E54-42B2-AE91-0F7D0D538F90Q34294774-0B426088-18A7-4EB8-AA67-8CF3A7191216Q34294838-B4502065-638B-43A5-9DEB-6044008B61D8Q34722706-6A521178-8213-4873-8E41-A638206D340DQ35150820-839B2FAC-F6C0-4DCE-BE81-263B640FE47AQ35230842-2DE5A84C-1437-479E-93FA-6CC155FE40A5Q35732096-30E754F9-3A46-4618-AB1A-5F4BBD067044Q35763902-3EB6A1D4-487E-491C-AE27-F99FDB31B30FQ36070394-2A45891F-DBE8-4CC9-B33F-A22374944D1AQ36611167-4CD91866-F515-4A2B-99D0-79A6395F6113Q36685373-4871B721-D7BB-4C09-B81C-9BF73347357BQ36829831-D75F8D47-0ADC-4B98-899B-33546DC9643FQ37234440-4AA8E0B3-5646-46D2-93B5-F67BC028091AQ37237427-033D9ECD-C01F-41D6-AC77-42CAF5606625Q37736316-6D3DA47A-F4BD-4B9A-ACF6-F8108DBBF709Q38560786-7F692152-8A65-4E0F-AF50-5526C53E9455Q38617612-17DB30B9-90C8-45DD-9FA0-5129F4939A3EQ38835171-4291DE63-5E5D-4C8E-A47A-102BAD1E7544Q39215653-8407BB3C-B07E-462D-9C99-E7E672830EDFQ40722959-7B133BBF-B2F1-4953-8A46-CE4C42CEAD97Q43922737-093C75A8-8066-4148-9CF7-8B574223B5DEQ44189939-772C6A88-B390-4D80-88C4-143A6955A94CQ44714539-94BD2079-3DB4-4F9C-B776-84DA91020B0CQ53898460-13B6B9C5-5C3C-4E14-9F59-B3D3BD8D65D4
P2860
Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Cytomegalovirus (CMV)-specific ...... sease after marrow transplant.
@en
type
label
Cytomegalovirus (CMV)-specific ...... sease after marrow transplant.
@en
prefLabel
Cytomegalovirus (CMV)-specific ...... sease after marrow transplant.
@en
P2093
P356
P1476
Cytomegalovirus (CMV)-specific ...... sease after marrow transplant.
@en
P2093
P304
P356
10.1093/INFDIS/164.3.483
P407
P577
1991-09-01T00:00:00Z